Inflammation-Induced Acute Phase Response in Skeletal Muscle and Critical Illness Myopathy

Objectives Systemic inflammation is a major risk factor for critical-illness myopathy (CIM) but its pathogenic role in muscle is uncertain. We observed that interleukin 6 (IL-6) and serum amyloid A1 (SAA1) expression was upregulated in muscle of critically ill patients. To test the relevance of these responses we assessed inflammation and acute-phase response at early and late time points in muscle of patients at risk for CIM. Design Prospective observational clinical study and prospective animal trial. Setting Two intensive care units (ICU) and research laboratory. Patients/Subjects 33 patients with Sequential Organ Failure Assessment scores ≥8 on 3 consecutive days within 5 days in ICU were investigated. A subgroup analysis of 12 patients with, and 18 patients without CIM (non-CIM) was performed. Two consecutive biopsies from vastus lateralis were obtained at median days 5 and 15, early and late time points. Controls were 5 healthy subjects undergoing elective orthopedic surgery. A septic mouse model and cultured myoblasts were used for mechanistic analyses. Measurements and Main Results Early SAA1 expression was significantly higher in skeletal muscle of CIM compared to non-CIM patients. Immunohistochemistry showed SAA1 accumulations in muscle of CIM patients at the early time point, which resolved later. SAA1 expression was induced by IL-6 and tumor necrosis factor-alpha in human and mouse myocytes in vitro. Inflammation-induced muscular SAA1 accumulation was reproduced in a sepsis mouse model. Conclusions Skeletal muscle contributes to general inflammation and acute-phase response in CIM patients. Muscular SAA1 could be important for CIM pathogenesis. Trial Registration ISRCTN77569430.

[1]  U. Machado,et al.  Identification of nuclear factor-κB sites in the Slc2a4 gene promoter , 2013, Molecular and Cellular Endocrinology.

[2]  Andreas Marg,et al.  Critical illness myopathy and GLUT4: significance of insulin and muscle contraction. , 2013, American journal of respiratory and critical care medicine.

[3]  C. Sprung,et al.  Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012 , 2013, Intensive Care Medicine.

[4]  J. Kress,et al.  Medical and Economic Implications of Physical Disability of Survivorship , 2012, Seminars in Respiratory and Critical Care Medicine.

[5]  C. Spies,et al.  Early type II fiber atrophy in intensive care unit patients with nonexcitable muscle membrane , 2012, Critical care medicine.

[6]  F. Filippin-Monteiro,et al.  Serum amyloid A is a growth factor for 3T3-L1 adipocytes, inhibits differentiation and promotes insulin resistance , 2011, International Journal of Obesity.

[7]  T. Zimmers,et al.  STAT3 Activation in Skeletal Muscle Links Muscle Wasting and the Acute Phase Response in Cancer Cachexia , 2011, PloS one.

[8]  J. Kirk-Bayley,et al.  Functional Disability 5 Years after Acute Respiratory Distress Syndrome , 2011 .

[9]  Alexander Doyle,et al.  Toll‐like receptor 4 mediates lipopolysaccharide‐induced muscle catabolism via coordinate activation of ubiquitin‐proteasome and autophagy‐lysosome pathways , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  K. Wernecke,et al.  Critical illness myopathy is frequent: accompanying neuropathy protracts ICU discharge , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[11]  C. Winkelman The role of inflammation in ICU-acquired weakness , 2010, Critical care.

[12]  K. Wernecke,et al.  Risk factors in critical illness myopathy during the early course of critical illness: a prospective observational study , 2010, Critical care.

[13]  J. Kinsella,et al.  Nonexcitable muscle membrane predicts intensive care unit-acquired paresis in mechanically ventilated, sedated patients. , 2010, Critical care medicine.

[14]  G. Supinski,et al.  Sepsis-induced myopathy. , 2009, Critical care medicine.

[15]  W. Mitch,et al.  IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. , 2009, Journal of the American Society of Nephrology : JASN.

[16]  G. Schuler,et al.  Induction of MuRF1 is essential for TNF-alpha-induced loss of muscle function in mice. , 2008, Journal of molecular biology.

[17]  S. Lemeshow,et al.  Acquired weakness, handgrip strength, and mortality in critically ill patients. , 2008, American journal of respiratory and critical care medicine.

[18]  D. Rittirsch,et al.  Immunodesign of experimental sepsis by cecal ligation and puncture , 2008, Nature Protocols.

[19]  Mi-Sung Kim,et al.  Myosin accumulation and striated muscle myopathy result from the loss of muscle RING finger 1 and 3. , 2007, The Journal of clinical investigation.

[20]  O. Friedrich Critical illness myopathy: what is happening? , 2006, Current opinion in clinical nutrition and metabolic care.

[21]  J. Lefaucheur,et al.  Origin of ICU acquired paresis determined by direct muscle stimulation , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[22]  D. West,et al.  Serum Amyloid A-Luciferase Transgenic Mice: Response to Sepsis, Acute Arthritis, and Contact Hypersensitivity and the Effects of Proteasome Inhibition , 2005, The Journal of Immunology.

[23]  C. Leeuwenburgh,et al.  Muscle fiber‐specific apoptosis and TNF‐α signaling in sarcopenia are attenuated by life‐long calorie restriction , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  T. Zimmers,et al.  Massive liver growth in mice induced by systemic interleukin 6 administration , 2003, Hepatology.

[25]  Isabelle Durand-Zaleski,et al.  Paresis acquired in the intensive care unit: a prospective multicenter study. , 2002, JAMA.

[26]  A. Whitehead,et al.  Serum amyloid A, the major vertebrate acute-phase reactant. , 1999, European journal of biochemistry.

[27]  Griffiths,et al.  Muscle fibre atrophy in critically ill patients is associated with the loss of myosin filaments and the presence of lysosomal enzymes and ubiquitin , 1998, Neuropathology and applied neurobiology.

[28]  K. Sletten,et al.  Mouse serum amyloid A (SAA) proteins isolated by two‐dimensional electrophoresis: characterization of isotypes and the effect of separate and combined administrations of cytokines, dexamethasone and lipopolysaccharide (LPS) on serum levels and isotype distribution , 1998, Clinical and experimental immunology.

[29]  S. Anker,et al.  Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. , 1997, Journal of the American College of Cardiology.

[30]  M. Kindy,et al.  Structure of the mouse Saa4 gene and its linkage to the serum amyloid A gene family. , 1996, Genomics.

[31]  M. Rich,et al.  Muscle is electrically inexcitable in acute quadriplegic myopathy , 1996, Neurology.

[32]  M. Yano,et al.  Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. , 1996, The Journal of clinical investigation.

[33]  A. Whitehead,et al.  A constitutively expressed serum amyloid A protein gene (SAA4) is closely linked to, and shares structural similarities with, an acute-phase serum amyloid A protein gene (SAA2). , 1993, Genomics.

[34]  C. Bolton,et al.  The neurological complications of sepsis , 1993, Annals of neurology.

[35]  P Franchimont,et al.  Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. , 1992, Annals of surgery.

[36]  J. Fischer,et al.  Evidence that tumor necrosis factor participates in the regulation of muscle proteolysis during sepsis. , 1992, Archives of surgery.

[37]  M. Goodman Tumor necrosis factor induces skeletal muscle protein breakdown in rats. , 1991, The American journal of physiology.

[38]  A. Waage,et al.  ASSOCIATION BETWEEN TUMOUR NECROSIS FACTOR IN SERUM AND FATAL OUTCOME IN PATIENTS WITH MENINGOCOCCAL DISEASE , 1987, The Lancet.

[39]  D. Potter,et al.  Structure of the murine serum amyloid A gene family. Gene conversion. , 1986, The Journal of biological chemistry.

[40]  A. Forrest,et al.  Letter: Procaine and malignant hyperthermia. , 1974, Lancet.